user
menu
letter
Sign InRegister
langEnglisharrow

Human Kallikrein 5 Protein, Tag Free (active enzyme)

Cat. No. / Size
Price
Availability
Qty
KA5-H5213-100ug
$350.00
In Stock - Delivery in 1-2 business days
KA5-H5213-1mg
$2,500.00
In Stock - Delivery in 1-2 business days
KA5-H5213
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
Request Quote
Product Details
Performance Data
Reviews & Citations
Resources
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

KLK-L2, KLKL2, SCTE

Source

Human Kallikrein 5 Protein, Tag Free (KA5-H5213) is expressed from human 293 cells (HEK293). It contains AA Ile 67 - Ser 293 (Accession # Q9Y337-1).

Predicted N-terminus: Ile 67

Molecular Characterization
Other Tags and Version Biotin & Other Labeled Version

This protein carries no "tag".

The protein has a calculated MW of 25.2 kDa. The protein migrates as 33-40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System

Background

Kallikrein 5(KLK5), a serine protease encoded by the KLK5 gene, regulates skin desquamation by activating kallikrein proteases (e.g., KLK7) and degrading corneodesmosomes. In cancer, KLK5 exhibits dual roles: while overexpressed in colorectal and pancreatic cancers promotes metastasis via ECM degradation, its elevated expression in breast cancer suppresses tumor growth by inhibiting RhoA and modulating the mevalonate pathway. Dysregulated KLK5 activity drives inflammatory skin disorders through excessive cleavage of cathelicidins. Therapeutic strategies include covalent inhibitors for inflammatory diseases and KLK5-enhancing approaches in breast cancer. Serum KLK5 levels serve as biomarkers for fibrosis and cancer prognosis.